The Brand Security Platform from ACG Inspection uses blockchain, the Internet of Things, and artificial intelligence technologies to track packages from manufacturer to consumer.
ACG Inspection, one of the four businesses of ACG Group, has introduced a blockchain-based solution that meets and exceeds traceability and anti-counterfeiting requirements in the pharmaceutical supply chain. The company’s Brand Security Platform combines GS1 2D Data Matrix, smart contracts, geolocation identification, and product biometrics tracking to monitor packaged medicines from manufacturer to end-user.
The system simplifies the overall process using distributed ledger technology and single ownership, which overcomes several longstanding obstacles to advanced traceability, including the challenges of establishing single-owner data sets and the prevalence of digitally broken supply chains. Each of the three primary components can be incorporated individually or bundled. The customizable products are scalable from basic data management to full-scale, supply chain-wide transparency.
Using blockchain-based distributed ledger technology (DLT) and smart contracts, all medicines and buyers, sellers, logistics partners, and manufacturers are registered to one network, so outsiders cannot manipulate the supply chain at any point without detection.
Using the Internet of Things, all participants in the delivery chain can be connected to the network using any GS1-compatible application, such as the ACG Inspection mobile application, the ACG Inspection web platform, or any other application integrated into the ACG Inspection platform. ACG Inspections geo-location and product biometrics trackers tagged to the products provide data required for monitoring the location information and biometrics of the package.
Participants can be alerted in real-time regarding any temperature outside specifications, geo-fencing breach, or any deviation in the route planning, enabling real-time decisions. Using artificial intelligence, if the data show unacceptable deviations, the corresponding package is automatically invalidated.
Upon obtaining a unique serial number, QR Code, or datamatrix for each package, the manufacturer scans the codes to initiate the track and trace process. From that point forward, the system’s trackers continuously monitor and transmit data concerning the package’s temperature, humidity, location, and any other configured parameter. Real-time data are available to platform users via a dashboard. The receiving party can validate the drug prior to purchase by scanning its code. Once the final transaction occurs, relevant data is immutably stored in a digital ledger for reporting or recall purposes.
Source:
ACG InspectionUnderstanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.